Navigation Links
Bioniche Reports Fiscal 2007 Year-End Results
Date:9/26/2007

- consolidated revenues rise 3% over Fiscal 2006 to $27.5 million -

(all figures are in Canadian dollars unless otherwise noted)

BELLEVILLE, ON, Sept. 26 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2007 fiscal year ended June 30, 2007.

"The recent announcements of the first shipment and commercial usage of our E. coli O157:H7 cattle vaccine and the Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration for our second Phase III pivotal trial in bladder cancer occurred after the end of Fiscal 2007, but are the result of significant internal efforts during the fiscal year," noted Patrick Montpetit, Chief Financial Officer of Bioniche Life Sciences Inc. "During Fiscal 2007, we started our first Phase III clinical trial using our proprietary Mycobacterial Cell Wall-DNA Complex (MCC) in the treatment of bladder cancer patients whose condition is refractory (unresponsive) to the current standard therapy. We also closed a $17.5 million equity financing, with strong support from both institutional and individual investors."

Fiscal 2007 Financial Results Highlights

Consolidated revenues for the fiscal year increased by 3% to $27.5 million, as compared to $26.7 million in Fiscal 2006. The overall gross profit margin was 56% this fiscal year as compared to 57% in Fiscal 2006.

Expenses totalled $18.5 million for the 12 months ending June 30, 2007, which compares to $19.6 million recorded in the same period last year. This decrease of $1.1 million, or 6%, includes a decrease in interest on long-term debt and other interest associated with the refinancing and repayment of the Company's debt.

Gross research and development (R&D) expenses increased $2 million, or 16%, in Fiscal 2007, reaching $14.9 million compared to $12.9 million in Fiscal 2006. This is largely atons 1,800 -

Unit issue costs incurred (1,906,316) (49,300)

Proceeds from convertible term note - 7,048,807

Payment of financing fees - debt - (1,333,986)

Proceeds from deferred government incentives 74,282 727,721

Proceeds from revolving credit facility 21,019,297 4,051,250

Repayment of revolving credit facility (21,677,375) (741,285)

Repayment of bridge loan - (8,605,500)

Repayment of senior and other long-term debt (3,300,296) (18,989,521)

-------------------------------------------------------------------------

Cash provided by (used in) financing activities 11,757,622 (8,107,571)

-------------------------------------------------------------------------

Net decrease in cash from continuing operations (2,569,696) (24,946,314)

Net increase in cash from discontinued operations - 25,512,199

-------------------------------------------------------------------------

Net increase (decrease) in cash for the year (2,569,696) 565,885

Cash and cash equivalents, beginning of year 4,093,293 3,527,408

-------------------------------------------------------------------------

Cash and cash equivalents, end of year 1,523,597 4,093,293

-------------------------------------------------------------------------

-------------------------------------------------------------------------

tributable to the start of the Phase III pivotal trial with Urocidin in bladder cancer patients whose condition is refractory (unresponsive) to the current standard therapy.

The Company repaid its long-term convertible debt with Laurus Master Funds during Fiscal 2007. US$1,723,307 was repaid on the secured convertible term note through conversion into shares and US$2,845,178 was repaid in cash. A secured revolving line of credit with Laurus Master Funds remains in place, allowing a maximum borrowing limit of US$4.0 million.

The basic net loss per share for Fiscal 2007 was ($0.32) compared to a net loss per share of ($0.03) in Fiscal 2006, which was bolstered by a gain of $0.47 per share from discontinued operations.

"We continue to pursue our strategic objectives with a view to creating shareholder value," added Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "We are focused on obtaining a full Canadian license for our E. coli O157:H7 cattle vaccine, while beginning to sell vaccine to Canadian veterinarians under the Permit to Release Veterinary Biologics. At the same time, we continue to pursue a registration in the U.S. We are also focused on the successful completion of a marketing partnership deal for our bladder cancer technology, while executing our Phase III clinical program with Urocidin and planning for early stage studies to support the use of our MCC technology in the treatment of other human cancers. Meeting these key milestones will, we believe, greatly enhance shareholder value in Bioniche."

Conference Call/Audio Web Cast

Bioniche will host a conference call to discuss Fiscal 2007 results on Friday, September 28, 2007 at 10:00 a.m. Eastern. To participate in the teleconference, call 416-644-3414/toll-free 1-800-733-7571. A listen-only audio web cast will be available at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2012120 (English) or http://www.cnw.ca/fr/webcast/viewEvent.cgi?eventID=2012120 (French).

A replay of the conference call will be available until October 5, 2007 by calling (416) 640-1917 or toll-free 1-877-289-8525 (passcode: 21247148 followed by the number sign). The web cast will be available for replay using the above links until December 28, 2007.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 195 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. For more information, please visit http://www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Bioniche Life Sciences Inc.

Amalgamated under the laws of Ontario

CONSOLIDATED BALANCE SHEETS

As at June 30 2007 2006

$ $

-------------------------------------------------------------------------

ASSETS

Current

Cash and cash equivalents 1,523,597 4,093,293

Short-term investments 9,500,000 -

Accounts receivable 5,495,836 5,644,956

Inventories 5,480,167 6,171,453

Prepaid expenses and deposits 658,867 804,470

-------------------------------------------------------------------------

22,658,467 16,714,172

-------------------------------------------------------------------------

Long-term

Property, plant and equipment 9,557,359 10,138,797

Intangible assets 8,545,215 9,401,733

Goodwill 456,155 456,155

Deferred financing fees 209,578 1,258,236

Investment - 3,298,279

Other assets 100,000 100,000

-------------------------------------------------------------------------

41,526,774 41,367,372

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current

Revolving credit facility 895,619 3,162,097

Accounts payable and accrued liabilities 6,399,382 5,054,593

Income and other taxes payable 283,845 494,881

Deferred government incentives 541,282 3,433,007

Current portion of long-term debt and capital

leases 123,769 1,220,840

-------------------------------------------------------------------------

8,243,897 13,365,418

-------------------------------------------------------------------------

Long-term

Long-term debt 421,396 3,697,806

Obligations under capital leases 764,933 953,957

Deferred government incentives 2,986,572 -

-------------------------------------------------------------------------

12,416,798 18,017,181

-------------------------------------------------------------------------

Shareholders' equity

Share capital 90,038,524 72,686,901

Special warrants 2,174,008 -

Other paid-in capital 5,528,059 4,556,290

Deficit (68,630,615) (53,869,621)

Cumulative translation adjustment - (23,379)

-------------------------------------------------------------------------

29,109,976 23,350,191

-------------------------------------------------------------------------

41,526,774 41,367,372

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Bioniche Life Sciences Inc.

CONSOLIDATED STATEMENTS OF DEFICIT

Years ended June 30

2007 2006

$ $

-------------------------------------------------------------------------

Deficit, beginning of year (53,869,621) (52,726,240)

Net loss (14,760,994) (1,143,381)

-------------------------------------------------------------------------

Deficit, end of year (68,630,615) (53,869,621)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Bioniche Life Sciences Inc.

CONSOLIDATED STATEMENTS OF LOSS

Years ended June 30

2007 2006

$ $

-------------------------------------------------------------------------

REVENUE

Sales 27,479,727 26,655,647

Cost of sales 12,179,266 11,331,332

-------------------------------------------------------------------------

Gross profit 15,300,461 15,324,315

-------------------------------------------------------------------------

EXPENSES

Administration 7,239,106 5,856,666

Marketing and selling 6,106,225 6,341,082

Quality assurance 690,291 1,208,459

Interest on long-term debt 637,510 1,538,130

Other interest 75,049 287,729

Accreted interest on convertible term note 722,867 379,554

Amortization of property, plant and equipment 1,169,948 1,217,731

Amortization of intangible assets 856,518 1,245,451

Amortization of deferred financing fees 1,048,658 1,357,835

Foreign exchange loss (gain) (55,375) 192,841

-------------------------------------------------------------------------

18,490,797 19,625,478

-------------------------------------------------------------------------

Loss before research and development expenses

and other items (3,190,336) (4,301,163)

Research and development expenses, gross 14,935,158 12,915,955

Less: government incentives, net (1,727,403) (833,148)

Loss on sale of investment 192,157 -

Gain on sale of rights to future royalty stream (2,127,587) -

Debt refinancing - 2,493,920

-------------------------------------------------------------------------

Loss from continuing operations before income

taxes (14,462,661) (18,877,890)

Provision for income taxes 298,333 112,094

-------------------------------------------------------------------------

Loss from continuing operations (14,760,994) (18,989,984)

Income from discontinued operations - 17,846,603

-------------------------------------------------------------------------

Net loss (14,760,994) (1,143,381)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic and fully diluted net income (loss) per share

Continuing operations (0.32) (0.50)

Discontinued operations - 0.47

-------------------------------------------------------------------------

Basic and fully diluted net loss per share (0.32) (0.03)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average number of common shares

outstanding 45,827,257 37,936,361

Bioniche Life Sciences Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Years ended June 30

2007 2006

$ $

-------------------------------------------------------------------------

OPERATING ACTIVITIES

Net loss from continuing operations (14,760,994) (18,989,984)

Add (deduct) non cash items:

Amortization 3,075,124 3,821,017

Accreted interest on convertible term note 722,867 498,881

Foreign exchange (gain) loss 38,208 (543,011)

Stock-based compensation 221,712 241,484

Warrants issued to consultants 39,300 -

Share bonus and shares issued to directors 962,759 90,002

Employee share ownership plan 523,559 544,872

Loss on sale of investment 192,157 -

Gain on sale of right to future royalty stream

and royalties recognized (2,618,306) -

Write-down of deferred costs - government

incentives - 576,000

Debt refinancing - 1,271,454

-----------------------------------------------------------------------

(11,603,614) (12,489,285)

Net change in non-cash working capital balances 615,806 (1,552,485)

-------------------------------------------------------------------------

Cash used in operating activities (10,987,808) (14,041,770)

-------------------------------------------------------------------------

INVESTING ACTIVITIES

Payment relating to acquisition of net assets - (123,120)

Acquisition of short-term investments (11,000,548) -

Proceeds from maturity of short-term investments 1,500,548 -

Government incentives received on account of

property, plant and equipment 30,224 54,422

Proceeds on disposal of property, plant and

equipment 4,786 11,888

Proceeds from sale (purchase) of investment 3,196,200 (1,740,146)

Selling costs incurred for sale of investment

and future royalty stream (100,000) -

Proceeds from sale of right to future royalty

stream 3,652,800 -

Purchase of property, plant and equipment (623,520) (1,000,017)

-------------------------------------------------------------------------

Cash used in investing activities (3,339,510) (2,796,973)

-------------------------------------------------------------------------

FINANCING ACTIVITIES

Proceeds from bridge loan - 8,681,250

Proceeds from units issued 17,500,000 1,102,993

Proceeds from over-allotment warrants issued 22,500 -

Proceeds from exercise of compensation warrants 23,730 -

Proceeds from exercise of stock opti
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016  Matchbook, Inc., a company specializing in ... companies, announced today the appointment of Jim ... brings nearly 25 years of experience in supply ... nearly two decades in executive level roles as ... Genzyme and, most recently headed global logistics and ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... ... SPIE Photonics West conference in San Francisco’s Moscone Center from February 16-18, ... same venue. , These latest InGaAs PIN diode standard packages feature a TO-46 ...
(Date:2/10/2016)... Boston, MA (PRWEB) , ... February 10, 2016 ... ... system is now available on Microsoft Azure. On Azure, Arvados provides capabilities for ... “We saw clear demand for Microsoft Azure from major institutions collecting and analyzing ...
(Date:2/10/2016)... ... February 09, 2016 , ... Creation Technologies, leading global ... Highest Overall Customer Rating Award from Circuits Assembly , today announced its milestone ... USA, Canada, Mexico and China. , The EMS provider, known in the EMS ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the world-leading ... and publication industries, will provide the data management solution ... (NPSC). ... Phenotypic analysis measures the ... organisms, allowing comparisons between states such as health and ...
(Date:1/21/2016)... --> ... report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, NLP, ... Voice Recognition and Others), Services, Application Areas, End ... published by MarketsandMarkets, the global Emotion Detection and ... Billion by 2020, at a CAGR of 31.9%, ...
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
Breaking Biology News(10 mins):